Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation
This report suggests asprosin as a novel therapeutic target for the treatment of type 2 diabetes through preservation of β-cell function.Graphical abstract
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Insulin | Obesity | Pancreas